Abraham Chachoua, MD
Dr. Abraham Chachoua is a thoracic oncologist and the Director of the Lung Cancer Center at the Perlmutter Cancer Center of NYU Langone. He specializes in treating thoracic cancers, including lung cancer and pleural mesothelioma. A recognized leader in lung cancer therapy, Dr. Chachoua became interested in the field of medicine, particularly in oncology, after his father’s diagnosis with multiple myeloma.[1]
Education and Career
Dr. Chachoua was born and raised in Australia and earned his medical degree at Monash University Faculty of Medicine.
He completed a residency in Oncology and a fellowship in Hematology and Oncology at Alfred Hospital in Melbourne, Australia, but with chemotherapy and other advances unavailable there, he moved to the United States to complete a research fellowship in medical oncology at NYU Langone.[1]
Dr. Chachoua is currently a medical and thoracic oncologist at NYU Langone’s Perlmutter Cancer Center in New York City. He specializes in treating lung cancer, mesothelioma, mediastinal tumors, and other thoracic cancers.
He is the Director of the Lung Cancer Program at the Perlmutter Cancer Center and the Section Chief of Medical Oncology. Dr. Chachoua is also the Antonio Magliocco, Jr. Professor of Medicine in the Department of Medicine at NYU Grossman School of Medicine.
Dr. Chachoua believes that communication is the key to good patient care. He says that he embarks on a journey with each patient, “trying to make the road better and smoother.” Dr. Chachoua is a member of the American Society of Clinical Oncology.
Research
Dr. Chachoua’s research interests center on the use of immunotherapy in treating lung cancer and pleural mesothelioma. The protocol allows physicians to harness the power of the immune system in a way that causes fewer side effects and higher rates of remission. He is also involved in several clinical trials for the treatment of non-small cell lung cancer.
He is particularly interested in the study of novel targeted therapies and how they can best be used in combination with chemotherapy for early-stage cancers as well as advanced thoracic malignancies.[1]
He is also researching the integration of multimodality approaches for the treatment of locally advanced lung cancer.
